Antipsychotic injectable extended release: A case report - 13/04/16
Résumé |
Objective |
To demonstrate the therapeutic efficacy of aripiprazole LP by a case of difficult clinical management and that we often find in our daily practice.
Methods |
Description of a clinical case of a 21-year-old man, recently diagnosed with paranoid schizophrenia with no awareness of disease neither treatment adherence and harmful use of THC and cocaine that are identified as precipitating factors for multiple hospital admissions.
Results |
Injectable medication with objective clinical improvement is significant, cessation of readmissions, achieving improvement in all parameters measured functionality and proper adherence to treatment as well as outpatient mental health of both devices as of drug dependence.
Conclusion |
Psychiatry is facing the great challenge of modifying the natural history to the deterioration of schizophrenia, a disease considered one of the leading causes of years lived with disability. The objectives medium and long-term treatment of this disease are centered on the delay-avoidance disability and improving the functioning and quality of life of people with this disease.
Le texte complet de cet article est disponible en PDF.Plan
Vol 33 - N° S
P. S618 - mars 2016 Retour au numéro
Article précédent
- The utility of omega-3 fatty acids in depression
- M.A. Quintanilla, A. Salas, S. Pedrosa, L. Bosqued, C. Perez, B. Villagrasa, B. Aguado, P. Gracia
- Adherence to treatment and number of relapses in patients treated with atypical antipsychotic prolonged release
- M.D.L.C. Ramirez Dominguez, I. Prieto Sánchez, M. Nuñez Caro, N. Garrido Torres, A.S. Biedma Martn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?